Technology
Health
Biotechnology

Syros

$8.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-2.18%) Today
-$0.20 (-2.18%) Today

Why Robinhood?

You can buy or sell Syros and other stocks, options, ETFs, and crypto commission-free!

About

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Read More The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Employees
76
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
302.54M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
148.25K
High Today
$8.97
Low Today
$8.75
Open Price
$8.97
Volume
11.47K
52 Week High
$13.86
52 Week Low
$5.17

Collections

Technology
Health
Biotechnology
Cancer Prevention
2016 IPO
US
North America
Female CEOs

News

Simply Wall StMar 13

What Should We Expect From Syros Pharmaceuticals, Inc.’s (NASDAQ:SYRS) Earnings In The Years Ahead?

Syros Pharmaceuticals, Inc.’s (NASDAQ:SYRS) most recent earnings announcement in December 2018 showed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Investors may find it useful to understand how market analysts view Syros Pharmaceuticals’s earnings growth outlook over the next couple of years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the unde...

30
The Motley FoolMar 7

Syros Pharmaceuticals, Inc. (SYRS) Q4 2018 Earnings Conference Call Transcript

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2018 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Quarter Four 2018 Syros Pharmaceuticals Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct the question-and-answer session and instructions will follow at that time. (Operator Instructions) I would n...

17
MarketBeatMar 5

Stock Price, News, & Analysis for Syros Pharmaceuticals

News stories about SYRS stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a news impact score of 1.1 on InfoTrie's scale. They also gave news articles about the company a ne...

0

Earnings

-$0.58
-$0.52
-$0.45
-$0.39
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.49 per share
Actual
-$0.54 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.